Loading...
FIXX logo

Homology Medicines, Inc.NasdaqGS:FIXX Stock Report

Market Cap US$54.3m
Share Price
n/a
US$27
n/aintrinsic discount
1Y-6.5%
7D3.8%
1D
Portfolio Value
​
View

Homology Medicines, Inc.

NasdaqGS:FIXX Stock Report

Market Cap: US$54.3m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Homology Medicines (FIXX) Stock Overview

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. More details

FIXX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap ($54M)

Does not have meaningful revenue ($1M)

Currently unprofitable and not forecast to become profitable over the next 3 years


FIXX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Homology Medicines, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Homology Medicines
Historical stock prices
Current Share PriceUS$16.82
52 Week HighUS$26.64
52 Week LowUS$8.24
Beta-0.11
1 Month Change8.42%
3 Month Change65.32%
1 Year Change-6.53%
3 Year Change-89.93%
5 Year Change-96.83%
Change since IPO-94.99%

Recent News & Updates

Recent updates

Analysis Article • Nov 16

Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Sep 06

Homology Medicines appoints new CEO, chairperson

Genetic medicines company Homology Medicines (NASDAQ:FIXX) promoted Chief Scientific Officer Albert Seymour to the position of CEO, president and board member. Seymour succeeds Arthur Tzianabos, who has been appointed as chairperson. Source: Press Release
Seeking Alpha • Jul 05

Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid

Homology Medicines (NASDAQ:FIXX) on Tuesday announced peer-reviewed publication of data on its AAVHSC16 capsid. FIXX stock earlier gained as much as 9.8% to a session high of $2.01 and was last up 3.3% in afternoon trading. According to the data, AAVHSC16 showed low levels of tropism to the liver while maintaining robust distribution to the central nervous system (CNS) and peripheral organs following a single intravenous injection in preclinical studies with rodents and primates. The preclinical data was peer-reviewed and published in the Molecular Therapy - Methods & Clinical Development journal. AAVHSC16 is a capsid, which is the protein shell of a virus that encloses its genetic material. AAVHSC stands for adeno-associated virus and hematopoietic stem cells, which are naturally occurring stem cells. FIXX's technology uses a family of 15 these types of cells to deliver genetic medicines. "In the case of AAVHSC16 with its ability to reach key tissues without targeting the liver in preclinical models, we can potentially expand into additional disease areas where we want to deliver to the CNS, cardiac tissue, or muscle while avoiding exposure in the liver," said FIXX chief scientific officer Albert Seymour.
Analysis Article • Jan 28

Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 22

Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online

Homology Medicines has built a unique gene therapy platform but has experienced a significant stock price decrease due to a COVID-related trial delay and controversy over its gene editing applications. The investment opportunity is to buy the stock on the premise that a resumption of the lead phase 2 trial will act as a positive catalyst for the stock price. The lead drug candidate, HMI-102, has the potential to become the standard-of-care in phenylketonuria, and any catalysts are likely to close the current valuation gap. Beyond the lead trial, Homology's platform has the potential to expand to CNS disorders, ophthalmological diseases, lung diseases, and more.
Analysis Article • Sep 18

We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 14

Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Homology Medicines, Inc. ( NASDAQ:FIXX ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • May 22

Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

Celebrations may be in order for Homology Medicines, Inc. ( NASDAQ:FIXX ) shareholders, with the analysts delivering a...
Analysis Article • Apr 17

Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Mar 13

Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Every investor in Homology Medicines, Inc. ( NASDAQ:FIXX ) should be aware of the most powerful shareholder groups...
Analysis Article • Feb 03

Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year

Homology Medicines, Inc. ( NASDAQ:FIXX ) shareholders should be happy to see the share price up 18% in the last...

Shareholder Returns

FIXXUS BiotechsUS Market
7D3.8%1.2%1.6%
1Y-6.5%35.9%28.5%

Return vs Industry: FIXX underperformed the US Biotechs industry which returned 10.2% over the past year.

Return vs Market: FIXX underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is FIXX's price volatile compared to industry and market?
FIXX volatility
FIXX Average Weekly Movement7.4%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: FIXX's share price has been volatile over the past 3 months.

Volatility Over Time: FIXX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20157n/awww.homologymedicines.com

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies.

Homology Medicines, Inc. Fundamentals Summary

How do Homology Medicines's earnings and revenue compare to its market cap?
FIXX fundamental statistics
Market capUS$54.34m
Earnings (TTM)-US$112.96m
Revenue (TTM)US$1.16m
47.0x
P/S Ratio
-0.5x
P/E Ratio

Is FIXX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FIXX income statement (TTM)
RevenueUS$1.16m
Cost of RevenueUS$62.00m
Gross Profit-US$60.85m
Other ExpensesUS$52.12m
Earnings-US$112.96m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-34.98
Gross Margin-5,263.49%
Net Profit Margin-9,771.71%
Debt/Equity Ratio0%

How did FIXX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/03/26 18:05
End of Day Share Price 2024/03/25 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Homology Medicines, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Jason ZemanskyBofA Global Research
Madhu KumarB. Riley Securities, Inc.